| Authors: |
Samain R; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK., Maiques O; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK., Monger J; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK., Lam H; School of Cancer and Pharmaceutical Sciences, Kings College London, London SE1 1UL, UK.; GSK, R&D Portfolio, Strategy and Business Insights, GSK House, 980 Great West Road, Brentford, TW8 9GS, UK., Candido J; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.; Oncology R&D, AstraZeneca, Cambridge CB21 6GH, UK., George S; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK., Ferrari N; Tumour Microenvironment Team, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.; Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., KohIhammer L; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK., Lunetto S; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London, London E1 2AT, UK., Varela A; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK., Orgaz JL; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.; Instituto de Investigaciones Biomédicas Sols-Morreale CSIC-UAM, 28029 Madrid, Spain., Vilardell F; Department of Pathology, University Hospital Arnau de Vilanova, University of Lleida, Lleida, Spain., Olsina JJ; Department of Surgery, University Hospital Arnau de Vilanova, University of Lleida, Lleida, Spain., Matias-Guiu X; Department of Pathology, University Hospital Arnau de Vilanova, University of Lleida, Lleida, Spain.; IRBLLEIDA, IDIBELL, University Hospita of Bellvitge, CIBERONC, Lleida, Spain., Sarker D; School of Cancer and Pharmaceutical Sciences, Kings College London, London SE1 1UL, UK., Biddle A; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London, London E1 2AT, UK., Balkwill FR; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK., Eyles J; Oncology R&D, AstraZeneca, Cambridge CB21 6GH, UK., Wilkinson RW; Oncology R&D, AstraZeneca, Cambridge CB21 6GH, UK., Kocher HM; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.; Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust, London, UK., Calvo F; Tumour Microenvironment Team, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.; Instituto de Biomedicina y Biotecnologia de Cantabria, c/ Albert Einstein 22, E39011 Santander, Spain., Wells CM; School of Cancer and Pharmaceutical Sciences, Kings College London, London SE1 1UL, UK., Sanz-Moreno V; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. |
